Drug Trial Radar · NCT02580305
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
564
Actual
Start
Sep 2015
Primary completion
Nov 5, 2019
Study completion Nov 7, 2019
Sponsor
- Lead sponsor
- Suven Life Sciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
Conditions
- Alzheimer's Disease
Interventions
SUVN-502Drug
Once-daily, tablets, orally
PlaceboDrug
Once-daily, tablets, orally
DonepezilDrug
Donepezil HCl (10 mg, once a day)
MemantineDrug
Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)Time frame: Baseline to Week 26
Locations
71 sites in 1 country. Site status is shown where the registry gives one.
Banner Alzheimer's Institute
Phoenix, Arizona
Barrow Neurological Institute
Phoenix, Arizona
Territory Neurology & Research Institute
Tucson, Arizona
ATP Clinical Research, Inc.
Costa Mesa, California
Neuro-Pain Medical Center Inc
Fresno, California
Neurology Center of North Orange County
Fullerton, California
Senior Clinical Trials, Inc.
Laguna Hills, California
Collaborative Neuroscience Network, LLC
Long Beach, California
Easton Center for Alzheimer's Disease Research at UCLA
Los Angeles, California
Paradigm Research
San Diego, California
Associated Neurologists of South Connecticut
Fairfield, Connecticut
JEM Research Institute
Atlantis, Florida
Bradenton Research Center, Inc
Bradenton, Florida
Brain Matters Research
Delray Beach, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
CCM Clinical Research Group
Miami, Florida
Collier Neurologic Specialists
Naples, Florida
Palm Beach Neurological Center
Palm Beach Gardens, Florida
Anchor Neuroscience
Pensacola, Florida
Emerald Coast Center for Neurological Disorders
Pensacola, Florida
Neurostudies Inc
Port Charlotte, Florida
The Roskamp Institute, Inc.
Sarasota, Florida
Brain Matters Research
Stuart, Florida
Neurology Clinical Research, Inc.
Sunrise, Florida
Axiom Clinical Research of Florida
Tampa, Florida
Olympian Clinical Research
Tampa, Florida
Stedman Clinical Trials
Tampa, Florida
University of South Florida - Byrd Alzheimer's Institute
Tampa, Florida
iResearch Atlanta, LLC
Decatur, Georgia
Advocate Lutheran General Hospital
Park Ridge, Illinois
Southern Illinois School of Medicine
Springfield, Illinois
Indiana University Health - University Hospital
Indianapolis, Indiana
Cotton-O'Neil Clinical Research Center
Topeka, Kansas
KU Medical Center Wichita Clinical Trial Unit
Wichita, Kansas
University Of Kentucky
Lexington, Kentucky
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Acadia Hospital
Bangor, Maine
Sheppard Pratt Health System
Baltimore, Maryland
Clinical Research Professionals
St Louis, Missouri
Princeton Medical Institute
Princeton, New Jersey
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.